| Overview |
| bs-9565r-pe-cy7-100ul |
| VMAT2 Polyclonal Antibody, PE-Cy7 Conjugated |
| WB |
| Human, Mouse, Rat |
| Specifications |
| PE-Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human VMAT2 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 3600 |
| MNAT; Monoamine neurotransmitter transporter; Monoamine transporter; Slc18a2; Solute carrier family 18 vesicular monoamine member 2; Solute carrier family 18 member 2; SVAT; SVMT; Synaptic vesicle amine transporter brain; Synaptic vesicle monoamine transporter brain; Synaptic vesicular amine transporter; VAT 2; VAT2; Vesicle monoamine transporter type 2; Vesicle monoamine/H+ antiporter; Vesicular amine transporter 2; Vesicular monoamine transporter 2; VMAT 2; VMAT2; VMAT2_HUMAN; 1110037L13Rik; 9330105E13; MGC120477; MGC120478; MGC26538; MGC90556. |
| Neurotransmission depends on the regulated exocytotic release of chemical transmitter molecules. This requires the packaging of these substances into the specialized secretory vesicles of neurons and neuroendocrine cells, a process mediated by specific vesicular transporters. The family of genes encoding the vesicular transporters of monoamines (VMAT 1 and VMAT 2) and acetylcholine (VACht) have been cloned and functionally characterized. The sequence of these integral membrane proteins predicts twelve transmembrane domains and weak homology to a class of bacterial antibiotic resistance proteins. The vesicular transport of neurotransmitter molecules has been shown to be an active ATP- and proton dependent transport mechanism. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz